Monoclonal antibodies, which have been successful in treating asthma, have been explored for the treatment of COPD. While triple therapy — which includes long-acting beta agonists, long-acting ...

Addressing the burden of patients living with chronic disease, Pfizer built on its pipeline of innovative hemophilia therapies, while Verona’s dual-action treatment for COPD offers a ...

Inhaled corticosteroids (ICS) are commonly prescribed for chronic obstructive pulmonary disease (COPD), but not recommended ...

Medically reviewed by Sanja Jelic, MD Asthma and chronic obstructive pulmonary disease (COPD) are chronic respiratory (lung) ...

Early diagnosis of COPD, chronic obstructive pulmonary disease, increases the quality of life of the patient and the efficacy ...

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD Following recent approvals in the EU, China, and the US, this approval was based on pivotal phase 3 results in ...

Significantly greater composite adverse outcome rates seen for long- versus short-term inhaled corticosteroid use for prevalent, inception cohorts.

Conclusion. In the treatment of COPD exacerbations, systemic corticosteroids improve airflow limitations, decrease treatment failure rates, decrease the risk of relapse, and may improve symptoms ...

Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils Approval marks the first new treatment approach for ...

Despite its established use in other conditions, the antibody is not yet approved for COPD treatment in any nation. The mepolizumab programme of the company in COPD includes three studies ...

EMA accepts for review GSK’s application to expand use of Nucala for COPD treatment: London, UK Wednesday, March 26, 2025, 11:00 Hrs [IST] GSK plc announced that the European Me ...